Gene Editing to Enhance the Efficacy of Cancer Cell Therapies

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2021 Oct 21

PMID 34673274

Citations 6

Authors

Tara Murty

Crystal L Mackall

Affiliations

Soon will be listed here.

Abstract

Adoptive T cell therapies have shown impressive signals of activity, but their clinical impact could be enhanced by technologies to increase T cell potency and diminish the cost and labor involved in manufacturing these products. Gene editing platforms are under study in this arena to (1) enhance immune cell potency by knocking out molecules that inhibit immune responses; (2) deliver genetic payloads into precise genomic locations and thereby enhance safety and/or improve the gene expression profile by leveraging physiologic promoters, enhancers, and repressors; and (3) enable off-the-shelf therapies by preventing alloreactivity and immune rejection. This review discusses gene editing approaches that have been the best studied in the context of human T cells and adoptive T cell therapies, summarizing their current status and near-term potential for translation.

Citing Articles

Cardiac myxoma: a comprehensive review.

Okongwu C, Olaofe O J Cardiothorac Surg. 2025; 20(1):151.

PMID: 40082903 PMC: 11905437. DOI: 10.1186/s13019-024-03333-2.

Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks.

Diorio C, Teachey D, Grupp S Nat Rev Clin Oncol. 2024; 22(1):10-27.

PMID: 39548270 DOI: 10.1038/s41571-024-00959-y.

The Confounding Role of Graft-Versus-Host Disease in Animal Models of Cancer Immunotherapy: A Systematic Review.

Ashraf H, Heydarnejad M, Kosari F Arch Iran Med. 2024; 27(3):159-167.

PMID: 38685841 PMC: 11097315. DOI: 10.34172/aim.2024.24.

Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.

Paschoudi K, Yannaki E, Psatha N Int J Mol Sci. 2023; 24(11).

PMID: 37298481 PMC: 10253463. DOI: 10.3390/ijms24119527.

Extracellular Vesicles as Delivery Vehicles for Therapeutic Nucleic Acids in Cancer Gene Therapy: Progress and Challenges.

Du R, Wang C, Zhu L, Yang Y Pharmaceutics. 2022; 14(10).

PMID: 36297672 PMC: 9610406. DOI: 10.3390/pharmaceutics14102236.

References

Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L . Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med. 2020; 26(5):732-740. DOI: 10.1038/s41591-020-0840-5. View

Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar O, Lucchini G . Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020; 396(10266):1885-1894. PMC: 11773457. DOI: 10.1016/S0140-6736(20)32334-5. View

Tschumi B, Dumauthioz N, Marti B, Zhang L, Lanitis E, Irving M . CART cells are prone to Fas- and DR5-mediated cell death. J Immunother Cancer. 2018; 6(1):71. PMC: 6045821. DOI: 10.1186/s40425-018-0385-z. View

Zeng J, Wu Y, Ren C, Bonanno J, Shen A, Shea D . Therapeutic base editing of human hematopoietic stem cells. Nat Med. 2020; 26(4):535-541. PMC: 7869435. DOI: 10.1038/s41591-020-0790-y. View

Tebas P, Stein D, Tang W, Frank I, Wang S, Lee G . Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014; 370(10):901-10. PMC: 4084652. DOI: 10.1056/NEJMoa1300662. View

Georgiadis C, Rasaiyaah J, Gkazi S, Preece R, Etuk A, Christi A . Base-edited CAR T cells for combinational therapy against T cell malignancies. Leukemia. 2021; 35(12):3466-3481. PMC: 8632682. DOI: 10.1038/s41375-021-01282-6. View

Mishra A, Kemler I, Dingli D . Preclinical development of CD126 CAR-T cells with broad antitumor activity. Blood Cancer J. 2021; 11(1):3. PMC: 7791061. DOI: 10.1038/s41408-020-00405-z. View

Webber B, Lonetree C, Kluesner M, Johnson M, Pomeroy E, Diers M . Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nat Commun. 2019; 10(1):5222. PMC: 6864045. DOI: 10.1038/s41467-019-13007-6. View

Ruder W, Lu T, Collins J . Synthetic biology moving into the clinic. Science. 2011; 333(6047):1248-52. DOI: 10.1126/science.1206843. View

10.

Kleinstiver B, Sousa A, Walton R, Tak Y, Hsu J, Clement K . Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nat Biotechnol. 2019; 37(3):276-282. PMC: 6401248. DOI: 10.1038/s41587-018-0011-0. View

11.

Rosenberg S, Packard B, Aebersold P, Solomon D, Topalian S, TOY S . Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988; 319(25):1676-80. DOI: 10.1056/NEJM198812223192527. View

12.

Seki A, Rutz S . Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells. J Exp Med. 2018; 215(3):985-997. PMC: 5839763. DOI: 10.1084/jem.20171626. View

13.

McGowan E, Lin Q, Ma G, Yin H, Chen S, Lin Y . PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. Biomed Pharmacother. 2019; 121:109625. DOI: 10.1016/j.biopha.2019.109625. View

14.

Jiang Y, Li Y, Zhu B . T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015; 6:e1792. PMC: 4669840. DOI: 10.1038/cddis.2015.162. View

15.

Petri K, Zhang W, Ma J, Schmidts A, Lee H, Horng J . CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells. Nat Biotechnol. 2021; 40(2):189-193. PMC: 8553808. DOI: 10.1038/s41587-021-00901-y. View

16.

Weisberg S, Carpenter D, Chait M, Dogra P, Gartrell-Corrado R, Chen A . Tissue-Resident Memory T Cells Mediate Immune Homeostasis in the Human Pancreas through the PD-1/PD-L1 Pathway. Cell Rep. 2019; 29(12):3916-3932.e5. PMC: 6939378. DOI: 10.1016/j.celrep.2019.11.056. View

17.

Murugan K, Babu K, Sundaresan R, Rajan R, Sashital D . The Revolution Continues: Newly Discovered Systems Expand the CRISPR-Cas Toolkit. Mol Cell. 2017; 68(1):15-25. PMC: 5683099. DOI: 10.1016/j.molcel.2017.09.007. View

18.

Kuhn N, Purdon T, van Leeuwen D, Lopez A, Curran K, Daniyan A . CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response. Cancer Cell. 2019; 35(3):473-488.e6. PMC: 6428219. DOI: 10.1016/j.ccell.2019.02.006. View

19.

Mastaglio S, Genovese P, Magnani Z, Ruggiero E, Landoni E, Camisa B . NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease. Blood. 2017; 130(5):606-618. DOI: 10.1182/blood-2016-08-732636. View

20.

Robbins P, Morgan R, Feldman S, Yang J, Sherry R, Dudley M . Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29(7):917-24. PMC: 3068063. DOI: 10.1200/JCO.2010.32.2537. View